7 results
#VisualAbstract for #Lancet trial #CANVASR #SGLT2i #Canagliflozin

"Canagliflozin and renal outcomes in type 2 diabetes: results from
#Lancet trial #CANVASR ... #SGLT2i #Canagliflozin ... outcomes in type 2 diabetes ... results from the CANVAS
Selected Clinical Trials of SGLT2 inhibitors in CVD and CKD
EMPA-REG OUTCOME - Empagliflozin lowered CV events
Clinical Trials of SGLT2 ... ASCVD; signal for SGLT2i ... CANVAS - Canagliflozin ... risk; signal for SGLT2i ... visualabstract #table
Diabetes Medications Summary Table
Insulin
Lifestyle modifications
Metformin
Sulfonylureas
GLP-1 receptor agonists - ↓ major adverse CV events
TZDs
DPP-4 inhibitors
SGLT2 inhibitors -
Diabetes Medications ... Summary Table ... -4 inhibitors SGLT2 ... EricsMedicalLectures/featured #diabetes ... #medications #table
Diagnostic criteria for diabetes flowchart. Visit gramproject.com for more medical diagrams, tables and flowcharts for use
Diagnostic criteria for diabetes ... medical diagrams, tables ... #diagnosis #algorithm ... #diabetes
Diabetes Mellitus Type 2 Inpatient Medication Guide

Classes: Biguanide, Sulfonylurea, TZD, DPP-4 inhibitor, GLP-1 receptor agonist, SGLT2i,
Diabetes Mellitus ... receptor agonist, SGLT2i ... insulin in Type 1 Diabetes ... monitors in Type 1 Diabetes ... pharmacology #comparison #table
Rybelsus (oral semaglutide) - First Oral GLP-1 Agonist
Dosing:
3 mg daily x 30 days, then 7 mg
drug to remain stable ... when compared to SGLT2 ... #semaglutide #Diabetes
Preoperative Risk Evaluation

Major Pre-Op Questions:
1. Does the patient have any modifiable risk factors that could be
functional status - Able ... metabolic equivalent able ... event, follow ACC algorithm ... Stable patients ... Diabetes regimen